Abstract
Small interfering RNAs (siRNA) are one of the most recent additions used to silence gene expression. At present, siRNA is the most extensively used gene-silencing technique over other nucleic-acid based approaches to treat diseases including cancer, hepatitis, respiratory disease, cardiovascular diseases, neuronal disease and autoimmune disease. However, systemic delivery of siRNA remains to be the biggest challenge to be overcome. Various strategies have been developed to deliver siRNA efficiently into target cell such as chemical modification of siRNA, physical strategies, viral and non viral-vectors mediated delivery. Among all the approaches non viral vectors including lipoplexes, polyplexes and inorganic nanoparticles were found to be most successful which have been reviewed in this article. Further therapeutic applications of RNAi have also been briefly reviewed.
Keywords: siRNA, Gene Silencing, viral vector, non-viral vector, polymeric systems
Current Gene Therapy
Title: siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Volume: 10 Issue: 2
Author(s): Bharat Khurana, Amit K. Goyal, Abhishek Budhiraja, Daisy Arora and Suresh P. Vyas
Affiliation:
Keywords: siRNA, Gene Silencing, viral vector, non-viral vector, polymeric systems
Abstract: Small interfering RNAs (siRNA) are one of the most recent additions used to silence gene expression. At present, siRNA is the most extensively used gene-silencing technique over other nucleic-acid based approaches to treat diseases including cancer, hepatitis, respiratory disease, cardiovascular diseases, neuronal disease and autoimmune disease. However, systemic delivery of siRNA remains to be the biggest challenge to be overcome. Various strategies have been developed to deliver siRNA efficiently into target cell such as chemical modification of siRNA, physical strategies, viral and non viral-vectors mediated delivery. Among all the approaches non viral vectors including lipoplexes, polyplexes and inorganic nanoparticles were found to be most successful which have been reviewed in this article. Further therapeutic applications of RNAi have also been briefly reviewed.
Export Options
About this article
Cite this article as:
Khurana Bharat, K. Goyal Amit, Budhiraja Abhishek, Arora Daisy and P. Vyas Suresh, siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing, Current Gene Therapy 2010; 10 (2) . https://dx.doi.org/10.2174/156652310791111010
DOI https://dx.doi.org/10.2174/156652310791111010 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry